Breaking News Instant updates and real-time market news.

MYL

Mylan

$36.47

-0.13 (-0.36%)

, PFE

Pfizer

$44.28

0.205 (0.47%)

06:34
10/02/18
10/02
06:34
10/02/18
06:34

EpiPen shortage shows company, regulator failure, FT says

The worldwide shortage of EpiPens shows a failure by Mylan (MYL), the company that owns the rights to the auto-injectors, and the regulators to monitor them, the Financial Times says, in an opinion piece by Michael Skapinker. Mylan did not pay enough to sub-contractor Pfizer's (PFE) performance and unnecessarily early expiration dates on the EpiPens increased sales but contributed to the shortage, according to Skapinker. Reference Link

MYL

Mylan

$36.47

-0.13 (-0.36%)

PFE

Pfizer

$44.28

0.205 (0.47%)

  • 03

    Oct

  • 03

    Oct

  • 10

    Oct

  • 17

    Oct

  • 22

    Oct

  • 30

    Oct

  • 13

    Nov

MYL Mylan
$36.47

-0.13 (-0.36%)

08/28/18
HCWC
08/28/18
INITIATION
Target $28
HCWC
Buy
Coherus Biosciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert started Coherus Biosciences (CHRS) with a Buy rating and $28 price target. The analyst expects approval of the company's Udencya in both the U.S. and Europe this year. His confidence level is driven by a positive recommendation from the European Committee for Medicinal Products for Human Use in July for marketing authorization of Udencya, a biosimilar compound targeting febrile neutropenia. Coherus announced that the committee reviewed all the new immunogenicity data that were required for the U.S. re-submission too, so the EU recommendation for approval adds a measure of confidence in support of U.S. approval, Kolbert tells investors in a research note. A year-end approval should position Udencya as the second biosimilar in the $4B U.S. marketplace behind Mylan (MYL), which should be launching its product following approval in June, the analyst adds.
08/30/18
GDHS
08/30/18
NO CHANGE
GDHS
Gordon Haskett questions Perrigo tie-up potential following call postponement
In a report published on August 20, Gordon Haskett analyst Don Bilson noted that Mylan (MYL) once claimed that it could generate $800M of synergies from a deal with Perrigo (PRGO) and while that dollar figure may no longer be relevant, the same logic may still be reasonably intact. At that time, he'd also pondered whether Mylan's failed attempt to acquire Perrigo in 2015-16 could be put back together given the troubles facing both companies. Gordon Haskett has flagged to investors that last night Perrigo postponed its investor event to discuss its long-term consumer growth strategies and key operational initiatives, previously planned as a conference call for September 25. Management had emphasized the event over 10 times on its earnings call just 3 weeks ago, the firm also noted.
09/06/18
WELS
09/06/18
NO CHANGE
WELS
Teva, Mylan weakness related to low multiple in Sandoz sale, says Wells Fargo
Wells Fargo analyst David Maris attributes today's weakness in shares of generic drugmakers Teva (TEVA) and Mylan (MYL) to the low sales multiple at which Novartis' (NVS) Sandoz unit is selling a portfolio of generic and branded products to Aurobindo. While Teva and Mylan clearly have very different businesses than the largely commodity and dermatology portfolio Sandoz is selling for $900M, Maris believes some investors are looking at the deal as a proxy for what the commodity portions of their U.S. businesses might be worth, he tells investors. Maris, who has previously voiced caution about generics and generic drug pricing, sees Novartis' deal as another indication that the environment remains challenging.
09/19/18
LEER
09/19/18
NO CHANGE
LEER
Outperform
Leerink 'incrementally positive on state of generics industry following meetings
Leerink analyst Ami Fadia tells investors in a research note that she is "incrementally positive" on the state of the generics industry following investor meetings with the management teams from Outperform-rated Amneal (AMRX), Pfenex and Teligent. Fadia says a key takeaway from the teams is that the FDA is placing additional emphasis on reviewing and approving complex generics, and while there is starting to be more first-to-market approvals, there are also more approvals for the second and third generic entrants. Additionally, Fadia says the complex generic opportunity will likely be characterized by a slower-than-typical launch ramp, but also extended duration of meaningful financial contribution due to less overall competitors vs that for oral-solid generics and that while companies still regard biosimilar assets as attractive, the low penetration for biosimilar Remicade in the U.S., Mylan's (MYL) slow start with Fulphila and extended litigation timelines mean management teams looking to participate in this space are taking a more prudent approach and minimizing their upfront investment.
PFE Pfizer
$44.28

0.205 (0.47%)

09/12/18
ADAM
09/12/18
NO CHANGE
Target $87
ADAM
Buy
Exact Sciences price target raised to $87 from $72 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Exact Sciences (EXAS) as he updated his model to include the contribution of Pfizer (PFE) reps. Massaro, who believes the company is well positioned to expand its business and he raised his estimates, reiterated his Buy rating on Exact Sciences shares.
09/18/18
JPMS
09/18/18
NO CHANGE
Target $81
JPMS
Overweight
Market evolving favorably for Ascendis into Phase III results, says JPMorgan
JPMorgan analyst Jessica Fye believes the long-acting growth hormone deficiency competitive landscape is evolving favorably for Ascendis Pharma heading into the Phase III results for the company's TransCon growth hormone in Q1 of 2019. The past 12-24 months has brought emerging clinical issues for all three of the key long-acting competitors, Fye tells investors in a research note. These range from the failure of Versartis (VSAR) at the most extreme, to the missed pivotal trial in adults for Pfizer (PFE) and Opko (OPK), to results that may raise questions around efficacy for Novo (NVO) in adults, Fye contends. The analyst believes these create opportunity for Ascendis, assuming the company is successful in Phase III. She continues to have high conviction in the success of the Phase III trial and keeps an Overweight rating on Ascendis Pharma with an $81 price target.
10/01/18
JPMS
10/01/18
NO CHANGE
Target $46
JPMS
Overweight
Pfizer price target raised to $46 from $42 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Pfizer to $46 on a revisit of the company's story. The analyst sees a "meaningful shift" in the Pfizer narrative away from potential acquisitions to the company's organic growth prospects post the Lyrica patent expiration in 2019. While he expects the company's growth will slow in 2019/2020, he sees a "distinct re-acceleration" of sales and earnings growth for Pfizer in the 2021-2025 period. Schott believes shares of Pfizer can further re-rate if the Street gains further confidence in its "sustained topline growth and capital deployment opportunities." The analyst keeps an Overweight rating on the shares.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.

TODAY'S FREE FLY STORIES

ECYT

Endocyte

$15.55

-0.4 (-2.51%)

, NVS

Novartis

$85.34

-0.41 (-0.48%)

09:16
10/18/18
10/18
09:16
10/18/18
09:16
Hot Stocks
Fly Intel: Pre-market Movers »

HIGHER: Endocyte (ECYT),…

ECYT

Endocyte

$15.55

-0.4 (-2.51%)

NVS

Novartis

$85.34

-0.41 (-0.48%)

ACOR

Acorda Therapeutics

$19.19

-0.7 (-3.52%)

PM

Philip Morris

$84.62

1.12 (1.34%)

AA

Alcoa

$36.71

0.51 (1.41%)

ERIC

Ericsson

$8.74

0.11 (1.27%)

SAP

SAP

$115.86

-1.56 (-1.33%)

TXT

Textron

$64.72

-2.01 (-3.01%)

SEE

Sealed Air

$35.28

-0.12 (-0.34%)

URI

United Rentals

$139.04

-2.15 (-1.52%)

ACRS

Aclaris Therapeutics

$12.14

-0.29 (-2.33%)

ADI

Analog Devices

$85.27

-0.48 (-0.56%)

MXIM

Maxim Integrated

$52.84

-0.13 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 05

    Jan

  • 18

    Oct

CSLT

Castlight Health

$2.62

0.04 (1.55%)

09:15
10/18/18
10/18
09:15
10/18/18
09:15
Recommendations
Castlight Health analyst commentary  »

William Blair sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 14

    Nov

DTRM

Determine

$0.58

-0.01 (-1.69%)

09:14
10/18/18
10/18
09:14
10/18/18
09:14
Hot Stocks
GTT choses Determine's procure-to-pay solution »

Determine announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PACW

PacWest Bancorp

$44.20

-0.14 (-0.32%)

09:13
10/18/18
10/18
09:13
10/18/18
09:13
Recommendations
PacWest Bancorp analyst commentary  »

PacWest Bancorp price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

PM

Philip Morris

$84.62

1.12 (1.34%)

09:13
10/18/18
10/18
09:13
10/18/18
09:13
Hot Stocks
Philip Morris says KFDA comments impacting those new to IQOS »

Says KFDA comments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ATOM

Atomera

$4.65

(0.00%)

09:12
10/18/18
10/18
09:12
10/18/18
09:12
Initiation
Atomera initiated  »

Atomera initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

CGIX

Cancer Genetics

$0.82

0.01 (1.23%)

09:10
10/18/18
10/18
09:10
10/18/18
09:10
Hot Stocks
Cancer Genetics enters strategic partnership with Genecast Biotechnology »

Cancer Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BL

BlackLine

$45.55

-0.01 (-0.02%)

, TRUE

TrueCar

$12.14

-0.1 (-0.82%)

09:10
10/18/18
10/18
09:10
10/18/18
09:10
Hot Stocks
BlackLine names Susan Otto as chief people officer »

BlackLine (BL) announced…

BL

BlackLine

$45.55

-0.01 (-0.02%)

TRUE

TrueCar

$12.14

-0.1 (-0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 13

    Nov

CCB

Coastal Financial

$16.25

0.05 (0.31%)

09:10
10/18/18
10/18
09:10
10/18/18
09:10
Hot Stocks
Coastal Financial hires Erika Heer as CHRO »

Coastal Financial hired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:10
10/18/18
10/18
09:10
10/18/18
09:10
General news
Fed dove Bullard said monetary policy is about right »

Fed dove Bullard said…

09:10
10/18/18
10/18
09:10
10/18/18
09:10
General news
The Philly Fed slipped to 22.2 »

The Philly Fed slipped to…

SPN

Superior Energy

$9.62

-0.25 (-2.53%)

09:09
10/18/18
10/18
09:09
10/18/18
09:09
Downgrade
Superior Energy rating change  »

Superior Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

PM

Philip Morris

$84.62

1.12 (1.34%)

09:09
10/18/18
10/18
09:09
10/18/18
09:09
Hot Stocks
Philip Morris sees Q4 net revenue down about 5%, reflecting difficult comps »

Says September YTD net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

IBM

IBM

$134.05

-10.97 (-7.56%)

, LNVGY

Lenovo

$0.00

(0.00%)

09:09
10/18/18
10/18
09:09
10/18/18
09:09
Hot Stocks
IBM signs $240M agreement with Lenovo for AI call center technology »

IBM (IBM) will supply…

IBM

IBM

$134.05

-10.97 (-7.56%)

LNVGY

Lenovo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 13

    Nov

  • 03

    Mar

TMO

Thermo Fisher

$234.64

-0.59 (-0.25%)

09:09
10/18/18
10/18
09:09
10/18/18
09:09
Downgrade
Thermo Fisher rating change  »

Thermo Fisher downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 24

    Oct

HAL

Halliburton

$39.56

-0.52 (-1.30%)

09:09
10/18/18
10/18
09:09
10/18/18
09:09
Downgrade
Halliburton rating change  »

Halliburton downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

STIM

Neuronetics

$22.50

-1.63 (-6.76%)

09:07
10/18/18
10/18
09:07
10/18/18
09:07
Recommendations
Neuronetics analyst commentary  »

Neuronetics fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

KEY

KeyCorp

$18.75

0.17 (0.91%)

09:07
10/18/18
10/18
09:07
10/18/18
09:07
Hot Stocks
KeyCorp sees Q4 average loans up low single digits »

Sees Q4 average deposits…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 30

    Oct

  • 16

    Nov

SAN

Banco Santander

$4.90

-0.085 (-1.71%)

09:07
10/18/18
10/18
09:07
10/18/18
09:07
Periodicals
German probe into share-swapping scheme spreads to Santander, FT reports »

Spain's Banco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$202.78

0.48 (0.24%)

09:05
10/18/18
10/18
09:05
10/18/18
09:05
Hot Stocks
Amgen invests $66M in Oxford Nanopore Technologies »

Amgen announced an equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 30

    Oct

  • 07

    Nov

  • 09

    Nov

FLS

Flowserve

$51.52

-0.29 (-0.56%)

09:04
10/18/18
10/18
09:04
10/18/18
09:04
Downgrade
Flowserve rating change  »

Flowserve downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYL

Xylem

$71.34

-0.4 (-0.56%)

09:04
10/18/18
10/18
09:04
10/18/18
09:04
Upgrade
Xylem rating change  »

Xylem upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

PNFP

Pinnacle Financial

$56.63

1.43 (2.59%)

09:04
10/18/18
10/18
09:04
10/18/18
09:04
Recommendations
Pinnacle Financial analyst commentary  »

Pinnacle Financial price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 26

    Nov

NUE

Nucor

$59.11

0.17 (0.29%)

09:04
10/18/18
10/18
09:04
10/18/18
09:04
Earnings
Breaking Earnings news story on Nucor »

Nucor reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

NUE

Nucor

$59.11

0.17 (0.29%)

09:03
10/18/18
10/18
09:03
10/18/18
09:03
Hot Stocks
Nucor CEO: We are on pace for 2018 to be a record year for earnings »

"The strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.